Spyre Therapeutics (SYRE) Shares Outstanding (Weighted Average) (2015 - 2026)
Spyre Therapeutics posted quarterly Shares Outstanding (Weighted Average) of $78.5 million for Q1 2026, up 30.34% year-on-year from $60.3 million in Q1 2025, and up 22.62% on a QoQ basis from $64.1 million in Q4 2025.
Spyre Therapeutics (SYRE) has 12 years of Shares Outstanding (Weighted Average) data on file, last reported at $78.5 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 30.34% year-over-year to $78.5 million; the trailing twelve-month figure through Mar 2026 stood at $78.5 million (up 30.34% YoY), and the FY2025 full-year result was $64.1 million, up 75076.56% from the prior year.
- Shares Outstanding (Weighted Average) for Q1 2026 stood at $78.5 million, up from $64.1 million in the prior quarter.
- Across five years, Shares Outstanding (Weighted Average) topped out at $78.5 million in Q1 2026 and bottomed at $16667.0 in Q3 2025.
- The 5-year median for Shares Outstanding (Weighted Average) is $5.2 million (2023), against an average of $29.4 million.
- The widest annual swing landed in 2024, when Shares Outstanding (Weighted Average) tumbled 98.63%; it then surged 75076.56% in 2025.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $3.2 million in 2022, then soared by 92.43% to $6.2 million in 2023, then sank by 98.63% to $85208.0 in 2024, then soared by 75076.56% to $64.1 million in 2025, then rose by 22.62% to $78.5 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $78.5 million (Q1 2026), $64.1 million (Q4 2025), and $16667.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - | 78.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 78.55 Mn |
| Dec 31, 2025 | 64.06 Mn |
| Sep 30, 2025 | 16,667.00 |
| Jun 30, 2025 | 60.30 Mn |
| Mar 31, 2025 | 60.27 Mn |
| Dec 31, 2024 | 85,208.00 |
| Sep 30, 2024 | 346,045.00 |
| Jun 30, 2024 | 45.32 Mn |
| Mar 31, 2024 | 166,261.00 |
| Dec 31, 2023 | 6.20 Mn |
| Sep 30, 2023 | 4.29 Mn |
| Jun 30, 2023 | 3.82 Mn |
| Mar 31, 2023 | 3.77 Mn |
| Sep 30, 2022 | 3.22 Mn |
| Jun 30, 2022 | 73.65 Mn |
| Mar 31, 2022 | 66.00 Mn |
| Dec 31, 2021 | 2.63 Mn |
| Sep 30, 2021 | 65.68 Mn |
| Jun 30, 2021 | 65.63 Mn |
| Mar 31, 2021 | 12.86 Mn |
| Dec 31, 2020 | 53.37 Mn |
| Sep 30, 2020 | 49.47 Mn |
| Jun 30, 2020 | 43.02 Mn |
| Mar 31, 2020 | 33.10 Mn |
| Dec 31, 2019 | 31.95 Mn |
| Sep 30, 2019 | 31.60 Mn |
| Jun 30, 2019 | 32.84 Mn |
| Mar 31, 2019 | 29.01 Mn |
| Dec 31, 2018 | 20.82 Mn |
| Sep 30, 2018 | 19.77 Mn |
| Jun 30, 2018 | 20.60 Mn |
| Mar 31, 2018 | 16.67 Mn |
| Dec 31, 2017 | 15.13 Mn |
| Sep 30, 2017 | 16.41 Mn |
| Jun 30, 2017 | 13.74 Mn |
| Mar 31, 2017 | 13.37 Mn |
| Dec 31, 2016 | 9.79 Mn |
| Sep 30, 2016 | 8.60 Mn |
| Jun 30, 2016 | 11.78 Mn |
| Mar 31, 2016 | 640,699.00 |
| Dec 31, 2015 | 599,788.00 |
| Sep 30, 2015 | 590,775.00 |
| Jun 30, 2015 | 579,520.00 |
| Mar 31, 2015 | 573,172.00 |